Perinuclear anti-neutrophil cytoplasmic antibodies (p-anca) in chronic ulcerative colitis: experience in a Mexican institution. 2006

Jesus K Yamamoto-Furusho, and Takeshi Takahashi-Monroy, and Omar Vergara-Fernandez, and Edgardo Reyes, and Luis Uscanga
Department of Gastroenterology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico.

OBJECTIVE To assess the prevalence and clinical value of p-ANCA in a sample of Mexican ulcerative colitis (UC) patients. METHODS In a prospective, IRB-approved protocol, p-ANCA was determined in 80 patients with UC (mean age, 32 +/- 12.9 years). The severity and extension of disease were determined by clinical methods, searching a statistical association with p-ANCA status. RESULTS p-ANCA were detected in 41 (51%) patients. Severity of disease was the only clinical variable statistically associated with their presence (P < 0.0001; OR = 9; CI 95% = 3.2-24.7). CONCLUSIONS The prevalence of p-ANCA was similar to that reported in other countries. Their presence was associated to UC severity, but offered no more information than the obtained by clinical methods.

UI MeSH Term Description Entries
D008297 Male Males
D008800 Mexico A country in NORTH AMERICA, bordering the Caribbean Sea and the Gulf of Mexico, between BELIZE and the UNITED STATES, and bordering the North Pacific Ocean, between Guatemala and the UNITED STATES.
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D003093 Colitis, Ulcerative Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN. Colitis Gravis,Idiopathic Proctocolitis,Inflammatory Bowel Disease, Ulcerative Colitis Type,Ulcerative Colitis
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012720 Severity of Illness Index Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder. Illness Index Severities,Illness Index Severity

Related Publications

Jesus K Yamamoto-Furusho, and Takeshi Takahashi-Monroy, and Omar Vergara-Fernandez, and Edgardo Reyes, and Luis Uscanga
March 1994, Journal of clinical pathology,
Jesus K Yamamoto-Furusho, and Takeshi Takahashi-Monroy, and Omar Vergara-Fernandez, and Edgardo Reyes, and Luis Uscanga
November 2017, Clinical chemistry and laboratory medicine,
Jesus K Yamamoto-Furusho, and Takeshi Takahashi-Monroy, and Omar Vergara-Fernandez, and Edgardo Reyes, and Luis Uscanga
February 1998, Clinical and experimental immunology,
Jesus K Yamamoto-Furusho, and Takeshi Takahashi-Monroy, and Omar Vergara-Fernandez, and Edgardo Reyes, and Luis Uscanga
January 1997, Clinical and experimental immunology,
Jesus K Yamamoto-Furusho, and Takeshi Takahashi-Monroy, and Omar Vergara-Fernandez, and Edgardo Reyes, and Luis Uscanga
January 1992, Nephrologie,
Jesus K Yamamoto-Furusho, and Takeshi Takahashi-Monroy, and Omar Vergara-Fernandez, and Edgardo Reyes, and Luis Uscanga
November 1990, Immunobiology,
Jesus K Yamamoto-Furusho, and Takeshi Takahashi-Monroy, and Omar Vergara-Fernandez, and Edgardo Reyes, and Luis Uscanga
January 2024, Ocular immunology and inflammation,
Jesus K Yamamoto-Furusho, and Takeshi Takahashi-Monroy, and Omar Vergara-Fernandez, and Edgardo Reyes, and Luis Uscanga
January 1993, Advances in experimental medicine and biology,
Jesus K Yamamoto-Furusho, and Takeshi Takahashi-Monroy, and Omar Vergara-Fernandez, and Edgardo Reyes, and Luis Uscanga
August 2021, Cells,
Jesus K Yamamoto-Furusho, and Takeshi Takahashi-Monroy, and Omar Vergara-Fernandez, and Edgardo Reyes, and Luis Uscanga
April 1998, Journal of clinical pathology,
Copied contents to your clipboard!